These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17059421)

  • 1. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.
    Nossent AY; VAN Marion V; VAN Tilburg NH; Rosendaal FR; Bertina RM; VAN Mourik JA; Eikenboom HC
    J Thromb Haemost; 2006 Dec; 4(12):2556-62. PubMed ID: 17059421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.
    Albánez S; Ogiwara K; Michels A; Hopman W; Grabell J; James P; Lillicrap D
    J Thromb Haemost; 2016 May; 14(5):953-63. PubMed ID: 26875505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
    Elsheikh E; Lavin M; Heck LA; Larkin N; Mullaney B; Doherty D; Kennedy M; Keenan C; Guest T; O'Mahony B; Fazavana J; Fallon PG; Preston RJS; Gormley J; Ryan K; O'Connell NM; Singleton E; Byrne M; McGowan M; Roche S; Doyle M; Crowley MP; O'Shea SI; Reipert BM; Johnsen JM; Pipe SW; Di Paola J; Turecek PL; O'Donnell JS;
    J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
    Ogiwara K; Swystun LL; Paine AS; Kepa S; Choi SJ; Rejtö J; Hopman W; Pabinger I; Lillicrap D
    J Thromb Haemost; 2021 Mar; 19(3):654-663. PubMed ID: 33219619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens.
    Morelli VM; de Visser MC; van Tilburg NH; Vos HL; Eikenboom JC; Rosendaal FR; Bertina RM
    Thromb Haemost; 2007 Apr; 97(4):534-41. PubMed ID: 17393014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
    Eikenboom J; Federici AB; Dirven RJ; Castaman G; Rodeghiero F; Budde U; Schneppenheim R; Batlle J; Canciani MT; Goudemand J; Peake I; Goodeve A;
    Blood; 2013 Mar; 121(12):2336-9. PubMed ID: 23349392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
    Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
    Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor.
    Rietveld IM; Lijfering WM; le Cessie S; Bos MHA; Rosendaal FR; Reitsma PH; Cannegieter SC
    J Thromb Haemost; 2019 Jan; 17(1):99-109. PubMed ID: 30471183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism.
    Tirado I; Mateo J; Soria JM; Oliver A; Martínez-Sánchez E; Vallvé C; Borrell M; Urrutia T; Fontcuberta J
    Thromb Haemost; 2005 Mar; 93(3):468-74. PubMed ID: 15735796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.
    Fischer K; Pendu R; van Schooten CJ; van Dijk K; Denis CV; van den Berg HM; Lenting PJ
    PLoS One; 2009 Aug; 4(8):e6745. PubMed ID: 19707594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.
    Ozel AB; McGee B; Siemieniak D; Jacobi PM; Haberichter SL; Brody LC; Mills JL; Molloy AM; Ginsburg D; Li JZ; Desch KC
    J Thromb Haemost; 2016 Sep; 14(9):1888-98. PubMed ID: 27359253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.
    Schleef M; Strobel E; Dick A; Frank J; Schramm W; Spannagl M
    Br J Haematol; 2005 Jan; 128(1):100-7. PubMed ID: 15606555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between ABO blood groups and von Willebrand factor, ADAMTS13 and factor VIII in patients undergoing hemodialysis.
    Rios DR; Fernandes AP; Figueiredo RC; Guimarães DA; Ferreira CN; Simões E Silva AC; Carvalho MG; Gomes KB; Dusse LM
    J Thromb Thrombolysis; 2012 May; 33(4):416-21. PubMed ID: 22466813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group.
    Davies JA; Collins PW; Hathaway LS; Bowen DJ
    J Thromb Haemost; 2008 Jan; 6(1):97-103. PubMed ID: 17949477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms and mutations in vWF and ADAMTS13 genes and their correlation with plasma levels of FVIII and vWF in patients with deep venous thrombosis.
    Bittar LF; de Paula EV; Mello TB; Siqueira LH; Orsi FL; Annichino-Bizzacchi JM
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):514-8. PubMed ID: 20682599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor.
    Gallinaro L; Cattini MG; Sztukowska M; Padrini R; Sartorello F; Pontara E; Bertomoro A; Daidone V; Pagnan A; Casonato A
    Blood; 2008 Apr; 111(7):3540-5. PubMed ID: 18245665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A.
    Rejtő J; Königsbrügge O; Grilz E; Hofer S; Mauracher LM; Gabler C; Schuster G; Feistritzer C; Sunder-Plaßmann R; Quehenberger P; Gebhart J; Ay C; Pabinger I
    J Thromb Haemost; 2020 May; 18(5):1081-1086. PubMed ID: 32073230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor.
    O'Donnell J; Laffan MA
    Transfus Med; 2001 Aug; 11(4):343-51. PubMed ID: 11532189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.